- Home
- RLTY vs ABEO Comparison
RLTY vs ABEO Comparison
Compare RLTY & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RLTY | ABEO |
|---|---|---|
| Founded | 2022 | 1974 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 262.5M | 399.5M |
| IPO Year | 2021 | 2005 |
Fundamental Metrics
Financial Performance| Metric | RLTY | ABEO |
|---|---|---|
| Price | $13.76 | $5.05 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $18.88 |
| AVG Volume (30 Days) | 53.3K | ★ 1.3M |
| Earning Date | 01-01-0001 | 11-11-2026 |
| Dividend Yield | ★ 9.35% | N/A |
| EPS Growth | N/A | ★ 165.16 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,998,000.00 |
| Revenue This Year | N/A | $804.33 |
| Revenue Next Year | N/A | $119.68 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 258.18 |
| 52 Week Low | $13.88 | $4.00 |
| 52 Week High | $16.41 | $7.65 |
Technical Indicators
Market Signals| Indicator | RLTY | ABEO |
|---|---|---|
| Relative Strength Index (RSI) | 17.11 | 35.55 |
| Support Level | N/A | $4.94 |
| Resistance Level | $15.92 | $5.46 |
| Average True Range (ATR) | 0.25 | 0.21 |
| MACD | -0.06 | -0.01 |
| Stochastic Oscillator | 0.00 | 11.39 |
Price Performance
Historical ComparisonAbout RLTY Cohen & Steers Real Estate Opportunities and Income Fund of Beneficial Interest
Cohen & Steers Real Estate Opportunities and Income Fund is a non-diversified, closed-end management statutory trust. Its primary investment objective is high current income. Its secondary investment objective is capital appreciation. The fund invests the majority of its managed assets in real estate-related investments and preferred and other income securities.
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.